Products

Bovine rotavirus A cDNA and Antigen

Cat#

Product Name

Swiss Prot#

Size

Price (US$)

Order

PN0139

Recombinant Protein-Bovine rotavirus A VP7 (a.a.51 to 326)

A8JNX7

100 µg

1195

Order

PN0140

Recombinant Protein-Bovine rotavirus A Outer capsid protein VP4 (a.a.30 to 269)

A8JNY1

100 µg

1195

Order

PN0141

Recombinant Protein-Bovine rotavirus A VP6 (a.a.21 to 397)

A8JNY5

100 µg

1195

Order

PN0142

Recombinant Protein-Bovine rotavirus A NSP5 (a.a.21 to 198)

A8JNY7

100 µg

1195

Order

RPN0139

 cDNA-Bovine rotavirus A VP7 (a.a.51 to 326)

A8JNX7

2 µg

1375

Order

RPN0140

 cDNA-Bovine rotavirus An Outer capsid protein VP4 (a.a.30 to 269)

A8JNY1

2 µg

1195

Order

RPN0141

 cDNA-Bovine rotavirus A VP6 (a.a.21 to 397)

A8JNY5

2 µg

1880

Order

RPN0142

 cDNA-Bovine rotavirus A NSP5 (a.a.21 to 198)

A8JNY7

2 µg

885

Order

Bovine rotavirus A cDNA and recombinant antigen

  • Codon-optimized cDNA is cloned into E. coli expression vector with 6x His-tag at N-terminus and ready-to-use for recombinant protein production.
  • Recombinant protein applications: Western Blot may be used for other applications determined by the user.
  • Protein Purity: >90%, as determined by SDS-PAGE under reducing conditions.
  • Protein Activity: N/A
  • Protein Tag:  Contains A 6x histidine tag at N-terminus.
  • Protein Formulation: Liquid
  • Source: Produced from E. coli

Bovine rotavirus A (BRVA) is a highly complex and multifaceted virus that has been found to infect the digestive tract of cattle, causing severe diarrhea and dehydration, ultimately resulting in weight loss in infected animals. This virus is characterized by its highly contagious nature and can spread rapidly throughout a herd, especially among young and vulnerable animals. The virus is excreted through the feces of infected animals and can be easily transmitted through contaminated feed, water, and equipment, further exacerbating the spread of the virus.

The BRVA genome, which is comprised of 11 segments of double-stranded RNA (dsRNA) that encode for at least six structural and non-structural proteins, plays a critical role in the replication and pathogenesis of the virus. The genetic information within the BRVA genome provides valuable insights into the molecular biology and evolution of rotaviruses, ultimately aiding in the development of improved diagnostic tools and vaccines to help control BRVA infection.

The bovine rotavirus A antigen, a substance recognized and specifically reacted to by the immune system of infected animals or those vaccinated against BRVA, is typically a protein or viral particle that helps stimulate the production of antibodies, ultimately offering protection against BRVA infection. The use of bovine rotavirus A antigen in vaccines has proven to be highly effective in reducing the incidence of BRVA-associated diarrhea and improving the overall health and productivity of infected cattle.

The BRVA virus is composed of several proteins, including A VP7, VP4, VP6, and NSP5, each of which plays a critical role in the pathogenesis and replication of the virus. A VP7 is an important viral protein involved in the formation of the outer layer of the virus particle and is a component of many rotavirus vaccines. VP4 is a viral protein that plays a crucial role in the attachment of the virus to host cells, as well as in the fusion of viral and host cell membranes during viral entry and is an important target for the host immune response to the virus. VP6, on the other hand, is a viral protein that forms the inner layer of the virus particle and is involved in the assembly and stabilization of the virus, while NSP5 is a non-structural protein that plays a vital role in the replication and transcription of the viral RNA.

Understanding the roles and functions of these different proteins of bovine rotavirus is crucial for developing effective strategies to prevent and treat infections in young calves. Rotavirus vaccines targeting VP7 and VP4 have already been developed and used to prevent rotavirus infections in calves and have been shown to be highly effective in reducing the incidence and severity of disease.

Moreover, the use of recombinant proteins/cDNA in academic research and therapeutic applications has become increasingly popular in recent years. However, successful recombinant protein expression in heterologous expression systems is dependent on various factors such as codon preference, RNA secondary structure, and GC content. Bioclone has developed a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones, which are cloned in E. coli expression Vector, and ready for the production of recombinant proteins. Experimental results have shown that the expression level of these recombinant proteins has dramatically increased, ranging from two to a hundred times depending on the gene, when compared to pre-optimization.

Welcome to BitClone

Magnetic Beads Make Things Simple